BeiGene CEO John Oyler at an Endpoints event in Shanghai, October 2018 (Credit: Endpoints News/PharmCube)

November 14, 2019 04:47 PM ESTUpdated November 18, 11:13 AM

In a first, FDA green-lights use of a Chinese built cancer therapy — and more are coming

Natalie Grover

Reporter

Weeks after Amgen took a $2.7 billion stake in BeiGene, the Beijing-based biotech has secured its first-ever FDA approval for zanubrutinib, a BTK inhibitor, months …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

In a first, FDA green-lights use of a Chinese built cancer therapy — and more are coming

Natalie Grover

Reporter

Sign up to read this article for free.

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take bluebird's Skysona gene therapy

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Bristol Myers sues the federal government over 340B, following other drugmakers

In a first, FDA green-lights use of a Chi­nese built can­cer ther­a­py — and more are com­ing

Natalie Grover

Reporter

Sign up to read this article for free.

more like this

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take blue­bird's Skysona gene ther­a­py

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

In a first, FDA green-lights use of a Chinese built cancer therapy — and more are coming

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take bluebird's Skysona gene therapy

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Bristol Myers sues the federal government over 340B, following other drugmakers